Anpheros Search · Treatment

Estetrol

Also known as: Fylrevy

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, estetrol is indicated as hormone replacement therapy for oestrogen deficiency symptoms in hysterectomised postmenopausal women. It is also indicated as hormone replacement therapy for oestrogen deficiency symptoms in non-hysterectomised postmenopausal women with at least 12 months since their last menses. Estetrol is listed by the cited source as having an approved use for unspecified menopausal or perimenopausal disorders.

Source: European Medicines Agency (EMA), Fylrevy — EPAR, 09/04/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

RxNorm
2539031 estetrol
EMA
EMEA/H/C/006213

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Fylrevy

Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in hysterectomised postmenopausal womenHormone replacement therapy (HRT) for oestrogen deficiency symptoms in non-hysterectomised postmenopausal women with at least 12 months since last menses.

Source: European Medicines Agency (EMA), Fylrevy — EPAR, 09/04/2026. © European Medicines Agency.

Document date: 09/04/2026 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Estetrol approved for in the European Union?

Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in hysterectomised postmenopausal womenHormone replacement therapy (HRT) for oestrogen deficiency symptoms in non-hysterectomised postmenopausal women with at least 12 months since last menses. (Source: European Medicines Agency (EMA), Fylrevy — EPAR, 09/04/2026. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Fylrevy — EPAR, 09/04/2026. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →